Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Sam M. Murray, M. Azim Ansari, John Frater, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 5, pp. 304-316
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1760-1774
Open Access | Times Cited: 84
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Spyros Chalkias, Jordan L. Whatley, Frank Eder, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2325-2333
Open Access | Times Cited: 50
Immune imprinting and next-generation coronavirus vaccines
Chloe Qingzhou Huang, Sneha Vishwanath, George Carnell, et al.
Nature Microbiology (2023) Vol. 8, Iss. 11, pp. 1971-1985
Closed Access | Times Cited: 44
Functional SARS-CoV-2 cross-reactive CD4 + T cells established in early childhood decline with age
Marion Humbert, Anna Olofsson, David Wullimann, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 12
Open Access | Times Cited: 42
The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.
Saulesh Kurmangaliyeva, Akzhan M. Madenbayeva, Saltanat T. Urazayeva, et al.
PubMed (2025) Vol. 50, Iss. 2, pp. 61-68
Closed Access | Times Cited: 2
Mechanisms of antibody-dependent enhancement of infectious disease
Timothy J. Wells, Tyron Esposito, Ian R. Henderson, et al.
Nature reviews. Immunology (2024)
Closed Access | Times Cited: 12
High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients
Pierre-Grégoire Coulon, Swayam Prakash, Nisha R. Dhanushkodi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Silent battles: immune responses in asymptomatic SARS-CoV-2 infection
Nina Le Bert, Taraz Samandari
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 2, pp. 159-170
Closed Access | Times Cited: 8
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Jiaying Shen, Junyan Fan, Yue Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
The role of SARS-CoV-2 N protein in diagnosis and vaccination in the context of emerging variants: present status and prospects
Wanchen Song, Zhongbiao Fang, Feike Ma, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 18
Divergent adaptive immune responses define two types of long COVID
Jérôme Kervevan, Isabelle Staropoli, Dorsaf Slama, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Net-Shaped DNA Nanostructure-Based Lateral Flow Assays for Rapid and Sensitive SARS-CoV-2 Detection
Saurabh Umrao, Mengxi Zheng, Xiaohe Jin, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 8, pp. 3291-3299
Closed Access | Times Cited: 8
A Nanoparticle Vaccine Displaying Conserved Epitopes of the Preexisting Neutralizing Antibody Confers Broad Protection against SARS-CoV-2 Variants
Xuefan Wu, Wei Li, Heng Rong, et al.
ACS Nano (2024) Vol. 18, Iss. 27, pp. 17749-17763
Closed Access | Times Cited: 8
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial
Matthijs P. Raadsen, Christine Dahlke, Anahita Fathi, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 7
SIRC epidemic model with cross-immunity and multiple time delays
Shashank Goel, Sumit Kaur Bhatia, Jai Prakash Tripathi, et al.
Journal of Mathematical Biology (2023) Vol. 87, Iss. 3
Closed Access | Times Cited: 13
Persistence of viral RNA in North American elk experimentally infected with an ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Paola M. Boggiatto, Alexandra Buckley, Eric D. Cassmann, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
Sam M. Murray, Elisa Pose, Melanie Wittner, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 1, pp. 109-123
Open Access | Times Cited: 12
Vaccine development against tuberculosis before and after Covid-19
Stefan H. E. Kaufmann
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity
Joud Mohammed Alkhalifah, Waleed Seddiq, Mohammed Alshehri, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 552-552
Open Access | Times Cited: 11
Transient anti-interferon autoantibodies in the airways are associated with efficient recovery from COVID-19
Benjamin Babcock, Astrid Kosters, Devon J. Eddins, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection
Fan Zhou, Juha Vahokoski, Siri Øyen, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits
Balasubramanian Arunachalam
Vaccines (2024) Vol. 12, Iss. 4, pp. 396-396
Open Access | Times Cited: 4
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development
Fabrizio Angius, Silvia Puxeddu, S Zaimi, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 17-17
Open Access | Times Cited: 4
Pre-existing IgG antibodies to HCoVs NL63 and OC43 Spike increased during the pandemic and after COVID-19 vaccination
Zahra Hasan, Kiran Iqbal Masood, Marc Veldhoen, et al.
Heliyon (2025) Vol. 11, Iss. 3, pp. e42171-e42171
Open Access
Analysis of the immune response in COVID-19
Altijana Hromić‐Jahjefendić, Alaa A. A. Aljabali
Progress in molecular biology and translational science (2025)
Closed Access
Page 1 - Next Page

Scroll to top